Disease Progression of WHIM Syndrome in an International Cohort of 66 Pediatric and Adult Patients.
Christoph B GeierMaryssa EllisonRachel CruzSumit PawarAlexander Leiss-PillerKatarina ZmajkovicovaShannon M McNultyMelis YilmazMartin Oman EvansSumai GordonBoglarka UjhaziIvana WiestHassan AbolhassaniAsghar AghamohammadiSara BarmettlerSaleh BharAnastasia BondarenkoAudrey Anna BolyardDavid BuchbinderMichaela CadaMirta CavieresJames A ConnellyDavid C DaleEkaterina DeordievaMorna J DorseySimon B DrysdaleStephan EhlReem ElfekyFrancesca FioreddaFrank FirkinElizabeth Förster-WaldlBob GengVera GodaLuis Gonzalez-GranadoEyal GrunebaumElzbieta GrzeskSarah E HenricksonAnna HilfanovaMitsuteru HiwatariChihaya ImaiWinnie IpSoma JyonouchiHirokazu KaneganeYuta KawaharaAmer M KhojahVy Hong-Diep KimMarina KojićSylwia KołtanGergely KrivanDaman LangguthYu-Lung LauDaniel LeungMaurizio MianoIrina MersyanovaTalal MousallemMica MuskatFlavio A NaoumSuzie A NoronhaMonia OuederniShuichi OzonoG Wendell RichmondInga SakovichUlrich SalzerCatharina SchuetzFiliz Odabasi SeeborgSvetlana O SharapovaKatja SockelAlla VolokhaMalte von BoninKlaus WarnatzOliver WegehauptGeoffrey A WeinbergKe-Juin WongAusten WorthHuang YuYulia ZharankovaXiaodong ZhaoLisa DevlinAdriana BadarauKrisztian CsomosMarton KeszeiJoao PereiraArthur G TaverasSarah L Beaussant-CohenMei-Sing OngAnna ShcherbinaJolan Eszter WalterPublished in: Journal of clinical immunology (2022)
Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome (WS) is a combined immunodeficiency caused by gain-of-function mutations in the C-X-C chemokine receptor type 4 (CXCR4) gene. We characterize a unique international cohort of 66 patients, including 57 (86%) cases previously unreported, with variable clinical phenotypes. Of 17 distinct CXCR4 genetic variants within our cohort, 11 were novel pathogenic variants affecting 15 individuals (23%). All variants affect the same CXCR4 region and impair CXCR4 internalization resulting in hyperactive signaling. The median age of diagnosis in our cohort (5.5 years) indicates WHIM syndrome can commonly present in childhood, although some patients are not diagnosed until adulthood. The prevalence and mean age of recognition and/or onset of clinical manifestations within our cohort were infections 88%/1.6 years, neutropenia 98%/3.8 years, lymphopenia 88%/5.0 years, and warts 40%/12.1 years. However, we report greater prevalence and variety of autoimmune complications of WHIM syndrome (21.2%) than reported previously. Patients with versus without family history of WHIM syndrome were diagnosed earlier (22%, average age 1.3 years versus 78%, average age 5 years, respectively). Patients with a family history of WHIM syndrome also received earlier treatment, experienced less hospitalization, and had less end-organ damage. This observation reinforces previous reports that early treatment for WHIM syndrome improves outcomes. Only one patient died; death was attributed to complications of hematopoietic stem cell transplantation. The variable expressivity of WHIM syndrome in pediatric patients delays their diagnosis and therapy. Early-onset bacterial infections with severe neutropenia and/or lymphopenia should prompt genetic testing for WHIM syndrome, even in the absence of warts.
Keyphrases
- early onset
- case report
- ejection fraction
- risk factors
- stem cells
- multiple sclerosis
- oxidative stress
- gene expression
- prognostic factors
- copy number
- metabolic syndrome
- dna methylation
- late onset
- newly diagnosed
- young adults
- genome wide
- patient reported outcomes
- insulin resistance
- transcription factor
- smoking cessation
- weight loss